In the Fall of 2020, monoclonal antibody therapy was approved by the FDA under the emergency use authorization for the treatment of COVID-19. Monoclonal antibody therapy introduces laboratory-produced molecules that act as substitute antibodies that can restore, enhance, or mimic the immune system’s attack on cells. Not long after the approval from the FDA, the leadership of Ortonville Area Health Services (OAHS) chose to offer the treatment in Ortonville, MN. “After looking at the data, we saw clear benefits,” explained Dr. Allan Ross, Chief Medical Officer at OAHS. “That led to us being one of the first facilities in the area to use monoclonal antibody therapy.” Dr. Ross continued, “I saw an article at the end of December of 2020 showing the number of infusions Massachusetts General Hospital (Harvard Medical School) had done. At that point, we had given more infusions at OAHS!”